tiprankstipranks
Advertisement
Advertisement

ANAB Stock Latest News

AnaptysBio Details Tax Treatment of Spin-Off Dividend
Company AnnouncementsAnaptysBio Details Tax Treatment of Spin-Off Dividend
8d ago
8K
ANAB
AnaptysBio Adjusts Fiscal Year-End and Reporting Calendar
PremiumCompany Announcements
AnaptysBio Adjusts Fiscal Year-End and Reporting Calendar
16d ago
8K
ANAB
AnaptysBio price target raised to $90 from $85 at Leerink
PremiumThe Fly
AnaptysBio price target raised to $90 from $85 at Leerink
22d ago
GSK
ANAB
AnaptysBio Split Raises Execution, Cost and Governance Risks as Royalty Dependence and Valuation Uncertainty Grow
PremiumCompany Announcements
AnaptysBio Split Raises Execution, Cost and Governance Risks as Royalty Dependence and Valuation Uncertainty Grow
24d ago
ANAB
AnaptysBio price target raised to $76 from $60 at UBS
PremiumThe Fly
AnaptysBio price target raised to $76 from $60 at UBS
25d ago
ANAB
AnaptysBio price target raised to $75 from $63 at Barclays
PremiumThe FlyAnaptysBio price target raised to $75 from $63 at Barclays
25d ago
ANAB
AnaptysBio reports Q1 EPS ($1.84), consensus (75c)
Premium
The Fly
AnaptysBio reports Q1 EPS ($1.84), consensus (75c)
25d ago
ANAB
AnaptysBio Appoints New CFO and Board Director
Premium
Company Announcements
AnaptysBio Appoints New CFO and Board Director
26d ago
8K
ANAB
AnaptysBio appoints Christopher Murphy as CFO
PremiumThe Fly
AnaptysBio appoints Christopher Murphy as CFO
26d ago
ANAB
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
PremiumThe Fly
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
1M ago
GSK
ANAB
AnaptysBio price target raised to $85 from $66 at Leerink
PremiumThe Fly
AnaptysBio price target raised to $85 from $66 at Leerink
1M ago
ANAB
GSK’s TESARO provides update on AnaptysBio litigation
PremiumThe Fly
GSK’s TESARO provides update on AnaptysBio litigation
1M ago
GSK
ANAB
Joseph Thome Reiterates Buy on AnaptysBio as Royalty-Focused Model and Jemperli Legal Win Support $75 Price Target
PremiumRatingsJoseph Thome Reiterates Buy on AnaptysBio as Royalty-Focused Model and Jemperli Legal Win Support $75 Price Target
1M ago
ANAB
Delaware court dismisses Tesaro breach of contract claim against AnaptysBio
Premium
The Fly
Delaware court dismisses Tesaro breach of contract claim against AnaptysBio
1M ago
GSK
ANAB
First Tracks Biotherapeutics initiated with an Outperform at Leerink
Premium
The Fly
First Tracks Biotherapeutics initiated with an Outperform at Leerink
1M ago
ANAB
TRAX
AnaptysBio price target lowered to $60 from $90 at UBS
PremiumThe Fly
AnaptysBio price target lowered to $60 from $90 at UBS
2M ago
ANAB
AnaptysBio price target lowered to $63 from $79 at Barclays
PremiumThe Fly
AnaptysBio price target lowered to $63 from $79 at Barclays
2M ago
ANAB
AnaptysBio price target lowered to $60 from $90 at UBS
PremiumThe Fly
AnaptysBio price target lowered to $60 from $90 at UBS
2M ago
GSK
ANAB
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
PremiumCompany Announcements
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
2M ago
8K
ANAB
AnaptysBio completes separation of First Tracks Biotherapeutics
PremiumThe FlyAnaptysBio completes separation of First Tracks Biotherapeutics
2M ago
ANAB
AnaptysBio price target raised to $95 from $67 at Piper Sandler
Premium
The Fly
AnaptysBio price target raised to $95 from $67 at Piper Sandler
2M ago
ANAB
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
Premium
Ratings
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
2M ago
ANAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >